Bacteraemic urinary tract infections in a tertiary hospital in Japan: the epidemiology of community-acquired infections and the role of non-carbapenem therapy

Table 3 Outcomes of patients with bacteraemia due to urinary tract infections caused by ESBL-producing Enterobacteriaceae

	CBP, N = 12	non-CBPBL, N = 7	P value*
14-day mortality	0%	0%	NA
Days to defervescence, median [IQR]	1.5 [1–4]	2 [1, 2]	0.74
Length of hospitalization after bacteraemia, median days [IQR]	24 [15–132]	13 [12–16]	0.08
Clinical cure	12 (100%)	6 (85.7%)	0.37
Microbiological cure	7 (58%)	4 (57%)	1.0

Data were compared between groups treated with empirical treatments (carbapenem vs. non-carbapenem beta-lactam)
ESBL, extended-spectrum beta-lactamase; CBP, carbapenem; non-CBPBL, non-carbapenem beta-lactam; IQR, interquartile range; NA, not available
* The sample size was not large enough to conduct accurate statistical analysis; thus, caution is necessary when interpreting the results

ISSN: 1756-0500